Preparation, characterization, and in vitro targeted delivery of folate-conjugated 2-methoxyestradiol-loaded bovine serum albumin nanoparticles
Source abstract
Abstract
The aim of this study was to prepare a novel targeting nano drug delivery system of 2-methoxyestradiol (2-ME) based on the folic acid-modified bovine serum albumin, in order to improve the clinical application disadvantages and antitumor effect of 2-ME. In this study, 2-methoxyestradiol-loaded albumin nanoparticles (2-ME-BSANPs) were prepared by desolvation method, and then the activated folic acid was conjugated to 2-ME-BSANPs by covalent attachment (2-ME-FA-BSANPs). The size and zeta potential of 2-ME-FA-BSANPs were about 208.8 ± 5.1 nm and −32.70 ± 1.01 mV, respectively. 2-ME loading efficiency and loading amount of the nanoparticles were 80.49 ± 3.80 and 10.25 ± 1.59 %, respectively. SEM images indicated that 2-ME-FA-BSANPs were of a round shape, similar uniform size, and smooth surface. Studies on drug release indicated that 2-ME-FA-BSANPs had the properties of sustained and controlled release, which provided them with the ability to fight continually against cancer cells. Internalization analysis demonstrated that 2-ME-FA-BSANPs-targeting drug delivery system could get efficiently transferred into the cells through the folic acid-mediated endocytosis, leading to higher apoptosis and affording higher antitumor efficacy against SMMC-7721 cells in vitro compared with 2-ME alone. Furthermore, the cell-cycle arrest of 2-ME-FA-BSANPs on the SMMC-7721 cells occurred at G2/M phase, and 2-ME-FA-BSANPs did not change the inhibition of the tumor mechanisms of 2-ME. Based on these results, it was concluded that albumin nanoparticles could be the promising nano carrier for 2-ME, and 2-ME-FA-BSANPs-targeting drug delivery system may be promising candidate for providing high treatment efficacy with minimal side effects in future cancer therapy.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Protein Interaction Studies and Fluorescence Analysis · Gold and Silver Nanoparticles Synthesis and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (31)
Show source-provided references
1. Birnbaum DT, Kosmala JD, Brannon-Peppas L (2000) Optimization of preparation techniques for poly (lactic acid-co-glycolic acid) nanoparticles. J Nanopart Res 2:173–181. doi: 10.1023/A:101003890876710.1023/A:1010038908767 ↗
2. Byrne JD, Betancourt T, Brannon-Peppas L (2008) Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 60(15):1615–1626. doi: 10.1016/j.addr.2008.08.00510.1016/j.addr.2008.08.005 ↗
3. Chen CQ, Zhang HJ, Hou L, Shi JJ, Wang L, Zhang CF, Zhang MY, Zhang HL, Shi XF, Li HX, Zhang ZZ (2013) Single-walled carbon nanotubes mediated neovascularity targeted antitumor drug delivery system. J Pharm Pharm Sci 16:41–50. www.cspsCanada.org10.18433/J3H02C ↗
4. Chuang VTG, Kragh-Hansen U, Otagiri M (2002) Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm Res 19:569–577. doi: 10.1023/A:101539682527410.1023/A:1015396825274 ↗
5. Dosio F, Arpico S, Stella B, Brusa P, Cattel L (2009) Folate-mediated targeting of albumin conjugates of paclitaxel obtained through a heterogeneous phase system. Int J Pharm 382:117–123. doi: 10.1016/j.ijpharm.2009.08.01810.1016/j.ijpharm.2009.08.018 ↗
6. Elzoghby AO, Samy WM, Elgindy NA (2012) Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release 157:168–182. doi: 10.1016/j.jconrel.2011.07.03110.1016/j.jconrel.2011.07.031 ↗
7. Gong J, Huo MR, Zhou JP, Zhang Y, Peng XL, Yu D, Zhang H, Li J (2009) Synthesis, characterization, drug-loading capacity and safety of novel octyl modified serum albumin micelles. Int J Pharm 376:161–168. doi: 10.1016/j.ijpharm.2009.04.03310.1016/j.ijpharm.2009.04.033 ↗
8. Gruner BA, Weitman SD (1999) The folate receptor as a potential therapeutic anticancer target. Invest New Drugs 16:205–219. doi: 10.1023/A:100614793215910.1023/A:1006147932159 ↗
9. Guo XH, Xing YB, Mei Q, Zhang HL, Zhang ZZ, Cui FD (2008) Preparation and cytotoxicity of 2-methoxyestradiol-loaded solid lipid nanoparticles. Anticancer Drugs 23:185–190. doi: 10.1097/CAD.0b013e32834cf8d0
10. Hao HP, Ma QM, Huang C, He F, Yao P (2013) Preparation, characterization, and in vivo, evaluation of doxorubicin loaded BSA nanoparticles with folic acid modified dextran surface. Int J Pharm 444:77–84. doi: 10.1016/j.ijpharm.2013.01.04110.1016/j.ijpharm.2013.01.041 ↗
11. Huang S, Wan Y, Wang Z, Jiliang W (2013) Folate-conjugated chitosan–polylactide nanoparticles for enhanced intracellular uptake of anticancer drug. J Nanopart Res 15:2096. doi: 10.1007/s11051-013-2096-110.1007/s11051-013-2096-1 ↗
12. Langer K, Balthasar S, Vogel V, Dinauer N, von Briesen H, Schubert D (2003) Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int J Pharm 257:169–180. doi: 10.1016/S0378-5173(03)00134-010.1016/S0378-5173(03)00134-0 ↗
13. Lee S, Murthy N (2007) Targeted delivery of catalase and superoxide dismutase to macrophages using folate. Biochem Biophys Res Commun 360:275–279. doi: 10.1016/j.bbrc.2007.06.05410.1016/j.bbrc.2007.06.054 ↗
14. Li FQ, Su H, Wang J, Liu YJ, Zhu QG, Fei YB, Pan YH, Hu JH (2008) Preparation and characterization of sodium ferulate entrapped bovine serum albumin nanoparticles for live targeting. Int J Pharm 349:274–282. doi: 10.1016/j.ijpharm.2007.08.00110.1016/j.ijpharm.2007.08.001 ↗
15. Lu Y, Low PS (2002) Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev 54:675–693. doi: 10.1016/j.addr.2012.0902010.1016/S0169-409X(02)00042-X ↗
16. Maruyama K (2011) Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. Adv Drug Deliv Rev 63(3):161–169. doi: 10.1016/j.addr.2010.09.00310.1016/j.addr.2010.09.003 ↗
17. Najafabadi AH, Abdouss M, Faghihi S (2014) Preparation and characterization of PEGylated chitosan nanocapsules as a carrier for pharmaceutical application. J Nanopart Res 16:2312. doi: 10.1007/s11051-014-2312-710.1007/s11051-014-2312-7 ↗
18. Patil GV (2003) Biopolymer albumin for diagnosis and in drug delivery. Drug Dev Res 58:219–247. doi: 10.1002/ddr.1015710.1002/ddr.10157 ↗
19. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R (2007) Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2(12):751–760. doi: 10.1038/nnano.2007.38710.1038/nnano.2007.387 ↗
20. Qi JN, Yao P, He F, Yu CL, Huang C (2010) Nanoparticles with dextran/chitosan shell and BSA/chitosan core-doxorubicin loading and delivery. Int J Pharm 393:176–184. doi: 10.1016/j.ijpharm.2010.03.063
21. Rahimnejad M, Jahanshahi M, Najafpour GD (2006) Production of biological nanoparticles from bovine serum albumin for drug delivery. Afr J Biotechnol 5(2006):1918–1923. doi: 10.4314/ajbv5i20.55912
22. Sabharanjak S, Mayor S (2004) Folate receptor endocytosis and trafficking. Adv Drug Deliv Rev 56:1099–1109. doi: 10.1016/j.addr.2004.01.01010.1016/j.addr.2004.01.010 ↗
23. Shi JJ, Zhang HL, Wang L, Li LL, Wang HH, Wang ZZ, Li Z, Chen CQ, Hou L, Zhang CF, Zhang ZZ (2013) PEI-derivatized fullerene drug delivery using folate as a homing device targeting to tumor. Biomaterials 34:251–261. doi: 10.1016/j.biomaterials.2012.09.03910.1016/j.biomaterials.2012.09.039 ↗
24. Sutherland TE, Anderson RL, Hughes RA, Altmann E, Schuliga M, Ziogas J et al (2007) 2-Methoxy estradiol-a unique blend of activities generating a new class of anti-tumour/anti-inflammatory agents. Drug Discov Today 12:577–584. doi: 10.1016/j.drudis.2007.05.00510.1016/j.drudis.2007.05.005 ↗
25. Wilbur DS, Chyan MK, Hamlin DK et al (2004) Reagents for astatination of biomolecules: comparison of the in vivo distribution and stability of some radioiodinated/astatinated benzamidyl and nido-carboranyl compounds. Bioconjug Chem 15:203–223. doi: 10.1021/bc034175k10.1021/bc034175k ↗
26. Yang L, Cui F, Cun DM, Tao A, Shi K, Lin WH (2007) Preparation, characterization and biodistribution of the lactone form of 10-hydroxycamptothecin (HCPT)-loaded bovine serum albumin (BSA) nanoparticles. Int J Pharm 340:163–172. doi: 10.1016/j.ijpharm.2007.03.02810.1016/j.ijpharm.2007.03.028 ↗
27. Zhang DW, Dougherty SA, Liang JL (2011) Fabrication of bovine serum albumin nanotubes through template-assisted layer by layer assembly. J Nanopart Res 13:1563–1571. doi: 10.1007/s1-011-0254-x10.1007/s11051-011-0254-x ↗
28. Zhang L, Hou S, Mao S, Wei D, Song X, Lu Y (2004) Uptake folate-conjugated albumin nanoparticles to the SKOV3 cells. Int J Pharm 287:155–162. doi: 10.1016/j.ijpharm.2004.08.01510.1016/j.ijpharm.2004.08.015 ↗
29. Zhao DM, Zhao XH, Zu YG, Li JL, Zhang Y, Jiang R, Zhang ZH (2010) Preparation, characterization, and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles. Int J Nanomed 5:669–677. doi: 10.2147/IJN.S12918
30. Zheng Y, Song SG, Darby M et al (2009) Preparation and characterization of folate-poly(ethylene glycol)-grafted-trimethylchitosan for intracellular transport of protein through folate receptor-mediated endocytosis. J Biotechnol 145:47–53. doi: 10.1016/j.jbiotec.2009.09.00710.1016/j.jbiotec.2009.09.007 ↗
31. Zhu XL, Huang SN, Xie YX et al (2014) Folic acid mediated solid lipid nanocarriers loaded with docetaxel and oxidized single-walled carbon nanotubes. J Nanopart Res 16:2207. doi: 10.1007/s11051-013-2207-z10.1007/s11051-013-2207-z ↗